Appraisal of the domestic kit «MICMICRO » for antimicrobial susceptibility testing by serial microdilution method

Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(3):231-236

​ Samoilova A.A., Kraeva L.A., Likhachev I.V., Rogacheva E.V., Verbov V.N., Mikhailov N.V., Zueva E.V.
10.36488/cmac.2020.3.231-236
antimicrobial resistance serial microdilution method colistin minimum inhibitory concentration
Section
Personal Experience
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(3):231-236

Objective.

To assess efficiency of the “MIC-MICRO” kit developed in the Department of New Technologies of the Saint-Petersburg Pasteur Institute, on reference strains and clinical bacterial isolates.

Materials and Methods.

In order to assess the “MIC-MICRO” kit, several options of its execution were used, including different groups of antibiotics: aztreonam, amikacin, gentamicin, colistin, meropenem, nitrofurantoin, chloramphenicol, cefotaxime, ceftriaxone, ciprofloxacin, erythromycin. In order to determine the range of antibiotic values, the EUCAST-2020 database was used. The quality control of adsorbed antibiotics was carried out using reference strains: Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213 and Escherichia coli NCTC 13846 (colistin-resistant). Acceptable and target ranges of MIC values for control strains are evaluated according to “Regular and extended internal quality control for determining MIC and disk diffusion according to EUCAST recommendations” (v10.0). A total of 28 clinical isolates of K. pneumoniae obtained from patients with nosocomial infections in St. Petersburg hospitals in 2018–2019 was used in the study. The coordination of test results was obtained in accordance with GOST R ISO 20776-1-2010. Susceptibility testing results were interpreted in accordance with EUCAST recommendations (v10.0).

Results.

The MIC values in relation to the reference strains obtained using the “MIC-MICRO” kit were determined in the range of recommended values of the EUCAST-2020 standard. The results obtained in relation to clinical isolates of K. pneumoniae showed that the sensitivity categories determined using the developed kit and the serial microdilution method were the same for all the studied strains. The percentage of colistin-resistant isolates (MIC > 2 mg/ml) in the serial microdilution method and determined using the “MIC-MICRO” kit was 35.7%. The percentage of susceptible strains was also similar for two types of methods (64.3%).

Conclusions.

Colistin susceptibility testing of K. pneumoniae strains using the “MIC-MICRO” diagnostic kit and the reference serial microdilution method in a tablet, showed comparable results. Diagnostic efficiency, ease to use and simple interpretation of results make it possible to use the developed “MIC-MICRO” kit in clinical laboratory practice.

Anna A. Samoilova

Pasteur Research Institute of Epidemiology and Microbiology, Saint-Petersburg, Russia

Kraeva L.A.

Pasteur Research Institute of Epidemiology and Microbiology, Saint-Petersburg, Russia

Likhachev I.V.

Pasteur Research Institute of Epidemiology and Microbiology, Saint-Petersburg, Russia

Rogacheva E.V.

Pasteur Research Institute of Epidemiology and Microbiology, Saint-Petersburg, Russia

Verbov V.N.

Pasteur Research Institute of Epidemiology and Microbiology, Saint-Petersburg, Russia

Mikhailov N.V.

Pasteur Research Institute of Epidemiology and Microbiology, Saint-Petersburg, Russia

Zueva E.V.

Pasteur Research Institute of Epidemiology and Microbiology, Saint-Petersburg, Russia

  • 1. Sidorenko S.V., Kolbin, A. S., Balykina J.E. The social and economic issues of acquired bacterial resistance. Klinicheskaja farmakologija i terapija. 2010;5:16-22. Russian.
  • 2. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations; 2016. O’Neill J. Review on Antimicrobial Resistance. Tackling drug resistant infections globally: final report and recommendations. 2016. Available at https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf. Accessed October 2020.
  • 3. Cerceo E., Deitelzweig S.B., Sherman B.M., Amin A.N. Multidrug-resistant gram-negative bacterial infection in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist. 2016;2:46-53. DOI: 10.1089/mdr.2015.0220
  • 4. Edelstein M.V., Skleenova E.Yu., Shevchenko O.V., Tapalski D.V., Azizov I.S., D’souza J.W. et al. Prevalence and Molecular Epidemiology of Gram-negative Bacteria Producing Metallo-blactamases (MBLs) in Russia, Belarus and Kazakhstan. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2012;14(2):132152. Russian.
  • 5. Kaye K.S., Pogue J.M. Infections caused by resistant gramnegative bacteria: epidemiology and management. Pharmacotherapy. 2015;35(10):949-962. DOI: 10.1002/phar.1636
  • 6. Sukhorukova M.V., Edelstein M.V., Ivanchik N.V., Skleenova E.Yu., Shajdullina E.R., Azyzov I.S. et al. Antimicrobial resistance of nosocomial Enterobacterales isolates in Russia: results of multicenter epidemiological study “MARATHON 2015-2016”. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2019;21(2):147159. Russian. DOI: 10.36488/cmac.2019.2.147-159
  • 7. Shamina O.V., Kryzhanovskaya O.A., Lazareva A.V., Polikarpova S.V., Karaseva O.V., Chebotar I.V., et al. The comparison of methods for determination of colistin susceptibility in carbapenem-resistant Klebsiella pneumoniae. Klinicheskaja laboratornaja diagnostika. 2018;63(10):646-650. Russian. DOI: 10.18821/0869-2084-2018-63-10-646-650
  • 8. Weiner L.M., Fridkin S.K., Aponte-Torres Z., Avery L., Coffin N., Dudeck M., et al. Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals. Morb Mortal Wkly Rep. 2016;65(9):235241. DOI: 10.15585/mmwr.mm6509e1
  • 9. Liu Y., Wang Y., Walsh T.R., Yi L.-X., Zhang R., Spencer J., et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human being in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161168. DOI: 10.1016/S1473-3099(15)00424-7
  • 10. Zuzov S.A., Zubkov M.M., Kononets P.V. Multidrug-resistant bacterial infections in the local general oncology hospital. Klinicheskij i jeksperimental'nyj hirurgicheskij zhurnal im. akademika B.V. Petrovskogo. 2016;2:25-34. Russian.
  • 11. Kuzovlev A.N., Shabanov A.K., Golubev A.M, Moroz V.V. Assessment of aerosolized colistin efficacy for nosocomial pneumonia. Obshhaja reanimatologija. 2017;13(6):6073. Russian. DOI: 10.15360/1813-9779-20176-60-73
  • 12. Sukhorukova M.V., Edelstein M.V., Skleenova E.Yu., Ivanchik N.V., Mikotina A.V., Dekhnich A.V., and the «MARATHON» study group. Antimicrobial resistance of nosocomial Enterobacteriaceae isolates in Russia: results of multicenter epidemiological study «MARATHON» 2013-2014. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2017;19(1):49-56. Russian.
  • 13. Volkova Y.V. Role of colistin in the treatment of nosocomial infection in patients of various types of intensive care units. Medicina neotlozhnyh sostojanij. 2018;2(89):17-22. Russian. DOI: 10.22141/22240586.2.89.2018.126597
  • 14. Vasoo S. Susceptibility testing for the polymyxins: two steps back, three steps forward? J Clin Microbiol. 2017;9:2573-2582. DOI: 10.1128/JCM.00888-17
  • 15. Tapalskiy D.V., Bilskiy I.A. Antimicrobial susceptibility testing by broth microdilution method: widely available modification. Klinicheskaja mikrobiologija i antimikrobnaja terapija. 2018;20(1):62-67. Russian. DOI: 10.36488/cmac.2018.1.62-67
  • 16. Turnidge J., Kahlmeter G., Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect. 2006;12:418-425. DOI: 10.1111/j.14690691.2006.01377.x
Views
0 Abstract
0 PDF
0 Crossref citations
Shared